Recently reported data in myelofibrosis patients, for example, demonstrated that doses in the 200–250 mg range combine with ruxolitinib to lessen disease burden and reduce spleen volumes compared to ruxolitinib alone, thus serving as a POC for BCL‐XL inhibition [70]. This evidence concerns the gene BCL2L1 and myelofibrosis.